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incidence of TRM at 5 years and 10 years was 40.0% and
42.5%, respectively. Multivariate analysis showed that pa-
tients with more than 5% circulating blasts (HR2.06, p¼0.05)
and more than 80% bone marrow blasts (HR2.35, p¼0.04)
were associated with poor survival. AML (HR0.42, p¼0.02)
and conditioning regimen of BU+MEL+TBI (HR0.46, p¼0.03)
were associated with better OS and DFS. SCT from unrelated
donors (HR4.01, p¼0.01) was independently associated with
increased TRM.
In conclusion, our data demonstrate that these intensiﬁed
myeloablative conditioning could be alternative regimens that
provide a long term durable remission and disease-free sur-
vival in patients with refractory hematologic malignancies.Figure 1.419
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Introduction: Hematologic malignancies are largely dis-
eases of older age. Advances in graft versus host disease
(GVHD) prophylaxis utilizing post-transplant cyclophos-
phamide (PTCy) expanded the use of haploidentical he-
matopoietic cell transplantation and has encouraging results
in non-haploidentical hematopoietic cell transplantation as
well. The Hopkins’ regimen using ﬂudarabine, cyclophos-
phamide, total body irradiation and post-transplant cyclo-
phosphamide (FluCyTBI-PTCy) has been associated with low
toxicity, and low rates of acute and chronic GVHD. Limited
data exist comparing the toxicity of this regimen in older
versus younger patients. We hypothesized this regimen
would be well tolerated in older patients.
Methods: We performed retrospective analysis of patients
who underwent allogeneic hematopoietic cell trans-
plantation utilizing FluCyTBI-PTCy regimen between 2009
and 2014 at our institution. Patients were eligible regard-
less of donor type or source. Patients were divided on the
basis of age (50 vs <50) and their transplant outcomes
assessed. Kaplan-Meier models were used to estimate
overall, disease free and event free survival. Cumulative
incidence was estimated using the method of Klein and
Moeschberger.
Results: A total of 46 patients were identiﬁed, 23 patients
were < 50 years of age at the time of their transplant.
Diagnoses included AML (61%), ALL (13%), AA (4%), NHL
(9%), MDS (7%), CML (4%), and CLL (2%). Age at transplant
was 19e73 years, with a median of 49. Donor sources
included: unrelated (15%), haploidentical (83%) and
matched sibling (2%). At transplant, active disease was
present in 3 / 6 ALL patients, 11 / 28 AML patients, 3 / 4NHL patients and 1 / 2 CML patients. Median overall sur-
vival (OS) was 17.9 months. There was no evidence of a
difference in OS by age category (p ¼ 0.74) (Figure 1). Non-
relapse mortality (NRM) at 6.5 months was 16.1% in the
overall population and 20.7% in older patients. There were
no differences in NRM by age category (p ¼ 0.90). Also, no
differences were seen in the median DFS or EFS by age
group (data not shown). Overall cumulative incidence of
relapse at 6 months was 26.9%. Cumulative incidence of
relapse in younger patients was 35.7% and 18.3% in older
patients (p ¼ 0.76). Similarly there was no statistically
signiﬁcant difference in the acute or chronic GVHD rates in
the two cohorts (data not shown).
Conclusions: There is limited data on outcomes of Hopkin’s
non-myeloablative FluCyTBI-PTCy transplant regimen in
older patients. Here we demonstrate outcomes in older pa-
tients that are comparable to those in younger patients.
Though limited by the small number of patients our results
suggest this regimen is safe with low NRM, and favorable OS.
The regimen provides a potentially curative option for older
patients without excess toxicity.
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Myeloﬁbrosis (MF), either primary (PMF) or post poly-
cythemia vera (PV), or essential thrombocythemia (ET)
affects older patients. JAK2 inhibitors can ameliorate
symptoms but allogeneic hematopoietic stem cell trans-
plantation (HSCT) remains the only curative option. In
recent years, reduced intensity conditioning (RIC) has
become the preferred transplant modality for MF. Higher
rates of graft failure (GF) have been noted in patients with
MF undergoing allogeneic HSCT as compared to other
diseases. Whether due to an abnormal marrow microen-
vironment, organomegaly or an expanded clonal stem cell
pool, GF leads to dismal outcomes.
Between 2008 and 2014, 42 patients, median age 58 (range
40-68, 22 with PMF (5/22 transformed to AML), 20 with
